04-11-2016

GGGNNNIIIPPPSSSTTT BBBUUULLLLLLEEETTTIIINNN 222000111666 04th November, 2016 Volume No.: 60 Issue No.: 03

Vision To develop responsible citizens who would be professionally equipped to ‘think globally and act locally’ and become reformers of society to meet the challenges of future.

Mission To impart high quality pharmaceutical science, technology and management education to the budding professionals and provide the ambience needed for developing requisite skills to make a mark of excellence in Education, Research, Business , Industry and achieve highest personal standards.

Contents • Message from PRINCIPAL• Editorial board• Historical article• News Update• Knowledge based Article• Disease Related Breaking News• Upcoming Events• Drugs Update• Campus News• Student’s Section• Editor’s Note

• Archive

GNIPST Photo Gallery For your comments/contribution

OR For Back-Issues, mailto:gnipstbulletin@gmail.com

GURU NANAK INSTITUTE OF PHARMACEUTICAL SCIENCE AND TECHNOLOGY

W e bs i t e : ht t p: / / gni ps t. a c. i n

04-11-2016

MESSAGE FROM PRINCIPAL

"It can happen. It does happen. But it can't happen if you quit." Lauren Dane.

‘We are what we repeatedly do. Excellence then is not an act, but a habit.’ Aristotle

It gives me immense pleasure to pen a few words for our e-bulletin. At the onset I would like to thank the last year’s editors and congratulate the newly selected editors for the current year.

Our first consideration is always in the best interest of the students. Our goal is to promote academic excellence and continuous improvement.

I believe that excellence in education is aided by creating a learning environment in which all learners are supported in maximizing their potential and talents. Education needs to focus on personalized learning and instruction, while promoting an education system that is impartial, universally accessible, and meeting the needs of all students.

It is of paramount importance that our learners have sufficient motivation and encouragement in order to achieve their aims. We are all very proud of you, our students, and your accomplishments and look forward to watching as you put your mark on the profession in the years ahead.

The call of the time is to progress, not merely to move ahead. Our progressive Management is looking forward and wants our Institute to flourish as a Post Graduate Institute of Excellence. Steps are taken in this direction and fruits of these efforts will be received by our students in the near future. Our Teachers are committed and dedicated for the development of the institution by imparting their knowledge and play the role of facilitator as well as role model to our students.

The Pharmacy profession is thriving with a multitude of possibilities, opportunities and positive challenges. At Guru Nanak Institute of Pharmaceutical Science and Technology, our focus is on holistic needs of our students.

I am confident that the students of GNIPST will recognize all the possibilities, take full advantage of the opportunities and meet the challenges with purpose and determination.

Excellence in Education is not a final destination, it is a continuous walk. I welcome you to join us on this path.

My best wishes to all.

Dr. A. Sengupta

Click here to go at the top

1

04-11-2016

EDITORIAL BOARD CHIEF EDITOR DR. ABHIJIT SENGUPTA EDITOR MS. JEENATARA BEGUM ASSOCIATE EDITOR MR. DIPANJAN

MANDAL

HISTORICAL ARTICLEIbn Rushd 1126-1198

Early Life: Abu Walid Mohammad Ibn Rushd born in 1128 C.E. in Cordova has been held as one of the greatest thinkers and scientists of the history. A product of twelfth-century Islamic Spain, he set out to integrate Aristotelian philosophy with Islamic thought. A common theme throughout his writings is that there is no inappropriateness between religion and philosophy when both are properly understood. His contributions to philosophy took many forms, ranging from his detailed commentaries on Aristotle, his defence of philosophy against the attacks of those who condemned it as different to Islam and his construction of a form of Aristotelianism which cleansed it, as far as was possible at the time, of, Neoplatonic influences. Contributions and Achievements: Ibn Rushd’s education followed a traditional path, beginning with studies in Hadith, linguistics, jurisprudence and scholastic theology. Throughout his life he wrote extensively on Philosophy and Religion, attributes of God, origin of the universe, Metaphysics and Psychology but he excelled in philosophy and jurisprudence and was nicknamed “the jurisprudent philosopher.” The role of the philosopher in the state was a topic of continual interest for Ibn Rushd. His thought is genuinely creative and highly controversial, producing powerful arguments that were to puzzle his

Click here to go at the top

2

04-11-2016

philosophical successors in the Jewish and Christian worlds. He seems to argue that there are two forms of truth, a religious form and a philosophical form, and that it does not matter if they point in different directions. He also appears to be doubtful about the possibility of personal immortality or of God’s being able to know that particular events have taken place. There is much in his work also which suggests that religion is inferior to philosophy as a means of attaining knowledge, and that the understanding of religion which ordinary believers can have is very different and impoverished when compared with that available to the philosopher. In philosophy, his most important work Tuhafut al-Tuhafut was written in response to Al-Ghazali’s work. Ibn Rushd was criticized by many Muslim scholars for this book, which, nevertheless, had a deep influence on European thought, at least until the beginning of modern philosophy and experimental science. His views on fate were that man is neither in full control of his destiny nor is it fully predetermined for him. Al Rushd’s longest commentary was, in fact, an original contribution as it was largely based on his analysis including interpretation of Quranic concepts. Ibn Rushd’s summary the opinions (fatwa) of previous Islamic jurists on a variety of issues has continued to influence Islamic scholars to the present day, notably Javed Ahmad Ghamidi. At the age of 25, Ibn Rushd conducted astronomical observations in Morocco, during which he discovered a previously unobserved star. He was also of the view that the Moon is opaque and obscure, and has some parts which are thicker than others, with the thicker parts receiving more light from the Sun than the thinner parts of the Moon. He also gave one of the first descriptions on sunspots. Ibn Rushd also made remarkable contributions in medicine. In medicine his well-known book Kitab al-Kulyat fi al-Tibb was written before 1162 A.D Its Latin translation was known as ‘Colliget’. In it Ibn Rushd has thrown light on various aspects of medicine, including the diagnoses, cure and prevention of diseases and several original observations of him.

Click here to go at the top

3

04-11-2016

He wrote at least 67 original works, which included 28 works on philosophy, 20 on medicine, 8 on law, 5 on theology, and 4 on grammar, in addition to his commentaries on most of Aristotle’s works and his commentary on Plato’s The Republic. A careful examination of his works reveals that Ibn Rushd (Averroes) was a deeply Islamic man. As an example, we find in his writing, “Anyone who studies anatomy will increase his faith in the omnipotence and oneness of God the Almighty”. He believed that true happiness for man can surely be achieved through mental and psychological health, and people cannot enjoy psychological health unless they follow ways that lead to happiness in the hereafter, and unless they believe in God and His oneness. Death: Ibn Rushd died in Marakesh in 1198 where he was buried. Three months later, his body was moved to Qurtuba, the tribune of his thought. It leaves no room for any doubt about the important influence that the Muslim Philosopher had on the greatest of all Catholic theologians.

NEWS UPDATE Rubella virus persists after vaccination in some

patients with immunodeficiency disorders: (04th November, 2016) Some patients with rare primary immunodeficiency disorders may be at risk for infection by rubella virus, and possibly serious skin inflammation, after receiving the rubella vaccine, usually administered as part of the measles-mumps-rubella (MMR) vaccine. Although the vaccine for rubella (German measles) has an established record of safety and effectiveness in the general population, patients with severe deficiencies in their immune defenses may be susceptible to side effects from the vaccine, say researchers.

Click here to go at the top

4

04-11-2016

Tumor cells in blood samples could predict prostate cancer spread: (04th November, 2016) Researchers have found a group of circulating tumor cells in prostate cancer patient blood samples that are linked to the spread of the disease, according to new research.

Scientists identify genetic markers of resistance to frontline malaria drug that could help control outbreaks: (04th November, 2016) Scientists have identified genetic markers associated with resistance to the one of the most commonly used malaria drugs in Southeast Asia. The findings of two independent studies from Cambodia could be used to help track and contain the spread of drug-resistant disease in the region.

Stem cell therapy appears to have TBI treatment effect: (03rd November, 2016)

Results of a cellular therapy clinical trial for traumatic brain injury (TBI) using a patient’s own stem cells showed that the therapy appears to dampen the body’s neuroinflammatory response to trauma and preserve brain tissue, according to researchers.

Researchers describe method to study real time cancer invasion: (03rd November, 2016) A research team has described the steps, in both written and video format, that allow cancer investigators to track, in real time, cancer cell invasion and metastasis in transparent zebrafish embryos. Using these fish models, researchers can find answers to cancer questions in one to three days instead of months for the typical mouse model.

Click here to go at the top

5

04-11-2016

Scientists advance understanding of how retinal cells are formed: (03rd November, 2016) Researchers have identified two genes—Tbx3 and Pax6—that together are sufficient to start the process of eye development.

Diagnosis of Alzheimer's disease: Llama antibodies detect cerebral lesions: (03rd November, 2016) The major challenge facing physicians treating Alzheimer's is the ability to detect markers of the disease as early as possible. These markers, located in the brain, are difficult to access, hampering diagnosis. Using two types of llama antibody capable of crossing the blood-brain barrier, scientists have developed a non-invasive approach to reach brain cells in a mouse model of the disease.

Research on pigment production reveals Achilles' heel for MRSA: (03rd November, 2016) A molecular explanation has been discovered for how the bacterium behind the super bug MRSA produces a red pigment that is crucial for its rapid growth.

Scientists identify bacterial genes that could lessen severity of malaria: (03rd November, 2016) A set of bacterial genes has been identified that may help researchers find ways to lessen the severity of the disease malaria. This findings could also aid the research of fellow scientists working in malaria-stricken regions around the world. For detail mail to editor

Click here to go at the top

6

04-11-2016

KNOWLEDGE BASED ARTICLE Accelerated approval to new treatment for

advanced soft tissue sarcoma

The grant is for accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues. Lartruvo is approved for use with the FDA-approved chemotherapy drug doxorubicin for the treatment of patients with STS who cannot be cured with radiation or surgery and who have a type of STS for which an anthracycline (chemotherapy) is an appropriate treatment. “For these patients, Lartruvo, added to doxorubicin, provides a new treatment option,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research and acting director of the FDA’s Oncology Center of Excellence. “This is the first new therapy approved by the FDA for the initial treatment of soft tissue sarcoma since doxorubicin’s approval more than 40 years ago.” The National Cancer Institute estimates that 12,310 new cases of STS and nearly 5,000 deaths are likely to occur from the disease in 2016. The most common treatment for STS that cannot be removed by surgery is treatment with doxorubicin alone or with other drugs. STS includes a wide variety of tumors arising in the muscle, fat, blood vessels, nerves, tendons or the lining of the joints. Lartruvo is a platelet-derived growth factor (PDGF) receptor-alpha blocking antibody. When stimulated, PDGF receptors cause tumor growth. Lartruvo works by blocking these receptors, which may help slow or stop tumor growth. The safety and efficacy of Lartruvo were studied in a randomized clinical trial involving 133 patients with more than 25 different subtypes of metastatic STS. Patients received either Lartruvo with doxorubicin or doxorubicin alone. This trial measured the length of time patients lived after treatment (overall survival), the length

Click here to go at the top

7

04-11-2016

of time tumors did not grow after treatment (progression-free survival) and the percentage of patients who experienced shrinkage of their tumors (overall response rate). Patients in this trial who received Lartruvo with doxorubicin had a statistically significant improvement in overall survival: the median survival was 26.5 months compared to 14.7 months for patients who received doxorubicin alone. Patients who received Lartruvo with doxorubicin had a median progression-free survival of 8.2 months compared to 4.4 months for patients who received doxorubicin alone. Tumor shrinkage was 18.2 percent for patients who received Lartruvo with doxorubicin and 7.5 percent for those who received doxorubicin alone. Lartruvo has serious risks including infusion-related reactions and embryo-fetal harm. Infusion-related reactions include low blood pressure, fever, chills and rash. The most common side effects of treatment with Lartruvo are nausea, fatigue, low levels of white blood cells (neutropenia), musculoskeletal pain, inflammation of the mucous membranes (mucositis), hair loss (alopecia), vomiting, diarrhea, decreased appetite, abdominal pain, nerve damage (neuropathy) and headache. The FDA granted the Lartruvo application fast track designation, breakthrough therapy designation and priority review status because preliminary clinical evidence indicated that it may offer a substantial improvement in effectiveness in the treatment of a serious or life-threatening disease or condition. The FDA is approving Lartruvo under the agency’s accelerated approval program, which allows approval of a drug to treat a serious or life-threatening disease or condition based on clinical data showing the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The sponsor is conducting a larger study, which is currently underway, to further explore the effectiveness of Lartruvo across the multiple subtypes of STS. Lartruvo also received orphan drug designation, which provides incentives such as tax credits, user fee waivers and eligibility for

Click here to go at the top

8

04-11-2016

exclusivity to assist and encourage the development of drugs intended to treat rare diseases.

Jeenatara Begum Assistant Professor

GNIPST DISEASE RELATED BREAKING NEWS

Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia: (31st October, 2016) Between 16 September and 10 October 2016 the National IHR Focal Point of Saudi Arabia seven (7) additional cases of Middle East Respiratory Syndrome (MERS) including one (1) fatal case. Read more

UPCOMING EVENTS IEEE forum-International conference on medical biological and

pharmaceutical sciences (ICMBPS) will be held on 5th November 2016 at Mumbai, Maharashtra, India.

5th Biennial conference DDNPTM-2016 will be held on 18th to 20th November, 2016 at National Institute of Pharmaceutical Education and Research (NIPER) SAS Nagar, Mohali, Punjab-160062.

DRUGS UPDATES FDA Approves Expanded Use of Enbrel (etanercept)

to Treat Children with Chronic Moderate-To-Severe Plaque Psoriasis: (04th November, 2016) Amgen (NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for the expanded use of Enbrel (etanercept), making it the first and only systemic

Click here to go at the top

9

04-11-2016

therapy to treat pediatric patients (ages 4-17) with chronic moderate-to-severe plaque psoriasis. Read more

CAMPUS NEWS International seminar 2016:

International seminar on Global Advancement in Pharmaceutical research and startup organized by GNIPST in collaboration with IPGA was held on 22nd October, 2016 at GNIPST auditorium.

NBA visit: The experts of National Board of Accreditation or NBA will be going to visit GNIPST on 24th September and 25th September, 2016.

Freshers welcome programme: On 12th September GNIPST organized the Freshers welcome programme Kulrav 2k16.

GNIPST Football Match 2016: On 31st August and 1st September GNIPST sports club organized a football match. The winner of the football match was B.Pharm 3rd year.

Recent Trends in Pharmaceutical Research: A Science Awareness Programme comprising of seminar on “Recent Trends in Pharmaceutical Research” was organized by GNIPST in collaboration with National Academy of Science India (NASI) on 30th august, 2016 from 2 pm to 4.30 pm at GNIPST auditorium. Plantation programme was also organized by Eco club. Dr. Hemanta Kumar Majumder, gave his valuable lecture on “Modern Biology & its Evolution” and Dr. Pijush K Das delivered his lecture on “Site specific Drug Targeting –Magic Bullet approach”.

Click here to go at the top

10

04-11-2016

World Photography Day celebration: On 19th August 2016 GNIPST celebrated World Photography Day at Dakhineswar.

Friendly Football Match: On 15th August 2016 GNIPST organised a friendly football match with Alumni members.

Farewell 2016: On 25th May 2016 GNIPST celebrated the farewell programme for the final year students. Best of luck to all final year students for their future life.

ALUMNI MEMBERS 2016: Congratulations to new Alumni Members of GNIPST.

Placement Record 2016: SL NO

COMPANY NAME NUMBER OF STUDENT

APPEARED/APPLIED

NUMBER OF STUDENT

SELECTED

JOB PROFILE

1 DR. LAL PATH LAB 64 7 Sales, Marketing and office assistant

2 APOLLO PHARMACY

36 25 Hospital and retail chain pharmacist

3 ABBOTT INDIA 74 03 Sales and Marketing

4 HETERO DRUGS 18 18 (Waiting for final

interview)

Production, QC and QA

5 ERIS LIFE SCIENCES 01 01 (Joined) Sales and Marketing

6 JUPITER PHARMACEUTICALS

05 01 (Joined) Production, QC and QA

7 GOVT PHARMACIST 4 4 (Joined) Hospital Pharmacist

8 ALCHEMIST EYE HOSPITAL

2 2 (Waiting for final

interview)

Hospital Pharmacist

Click here to go at the top

11

04-11-2016

9 OPTIVAL HEALTH SOLUTIONS PVT. LTD. (MEDPLUS)

21 21 Community Pharmacist

10 NESTLE INDIA LTD 08 02 Nutrition Officer Trainee

11 LUPIN 01 01 Sales and Marketing

12 GSK PHARMACEUTICAL

LTD

05 02 (1 of them already joined)

Sales and Marketing

13 OAK PHARMACEUTICAL

06 02 (Joined) Sales and Marketing

IPA Bengal Pharma & Healthcare trust scholarship 2016: Congratulations to Rudradip Das, student of B.Pharm 3rd year has been awarded IPA Bengal Pharma & Healthcare trust scholarship 2016.

Accreditation by NAAC: SL. NO.

NAME OF THE INSTITUTE

STATE CGPA(out of scale 4)

GRADE

01 Guru Nanak Institute of Pharmaceutical Science And Technology, Kolkata-700114

West Bengal

2.70 B

GPAT 2016 Result: The following B.Pharm. final year students have qualified, GPAT-2016. We congratulate them all. Aishika Datta Mainak Chatterjee Indira Saha Priyanka De

Click here to go at the top

12

04-11-2016

Aheli Mukherjee Soumya Guha Debanjana Das Debalina Datta Evana Patra Himadrija Chatterjee

IRIS 2016: GNIPST organized colllege fest ‘IRIS 2016’ from 11th to 13th March, 2016. Result of different events: Intracollege Quiz competition: 1st: Arani Roy and Dipayan Nath 2nd: Bhaskar Singha and Pratik Nandi Intracollege Painting competition: 1st: Swagata Paul 2nd: Aviraj Pathak 3rd: Dippyoman Guha Group Dance Competition: Karma Group Intercollege Solo Dance Competition: 1st : Monodipa Ghosh 2nd: Aditya Paul (NIT) Antaksari Competition: 1st: Sunanda and Aparupa 2nd: Meghna and Joyita 3rd: Arpita and Pami Intercollege Solo Singing Competition: 1st: Arpita Sarkar 2nd: Arvind Raj (Sudhir Chandra College) 3rd: Priyam Mondal (Supreme College) Intercollege Band Competition:

Click here to go at the top

13

04-11-2016

1st: D Errors 2nd: Mukti 3rd: GNIPST band Fashion: Best Male: Md. Nadeem Shah Best Female: Sweta Best Couple: Md. Nadeem Shah and Susmita Kar

Blood donation Camp 2016: On 4th March 2016 Social Service club and Alumni Association of GNIPST organized a Blood donation camp in association with Association of voluntary Blood Donars, West Bengal.

Reminiscence & 1st Alumni meet 2016: On 28th February 2016 GNIPST organized the Reunion programme “Reminiscence & 1st Alumni meet 2016”.

National Assessment and Accreditation Council (NAAC): A NAAC peer team completed a three-day inspection (17th February to 19th February, 2016) of GNIPST to evaluate its academic credibility and infrastructure on Friday.

Saraswati Puja 2016: On 13th February 2016 the students of GNIPST celebrated Saraswati Puja at GNIPST campus.

STUDENTS’ SECTION WHO CAN ANSWER FIRST????

Which lymphatic disease is named after thisnscientist?

Click here to go at the top

14

04-11-2016

Answer of Previous Issue’s Image:

Dorothy Crowfoot Hodgkin

Send your thoughts/ Quiz/Puzzles/games/write-ups or any other contributions for Students’ Section& answers of this Section at gnipstbulletin@gmail.com

EDITOR’S NOTE It is a great pleasure for me to publish the 3rd issue of 60th Volume of GNIPST BULLETIN. All the followers of GNIPST BULLETIN are able to avail the bulletin through facebook account ‘GNIPST bulletin’ I am very much thankful to all the GNIPST members and readers who are giving their valuable comments, encouragements and supports. I am also thankful to Dr. Abhijit Sengupta, Director of GNIPST for his valuable advice and encouragement. Special thanks to Dr. Prerona Saha, Mr. Debabrata Ghosh Dastidar and Mr. Soumya Bhattacharya for their kind co-operation and technical supports. Thank you Mr. Soumya Bhattacharya for the questionnaires of the student section. An important part of the improvement of the bulletin is the contribution of the readers. You are invited to send in your write ups, notes, critiques or any kind of contribution for the forthcoming special and regular issue.

ARCHIVE OTHERS: AICTE has sanctioned a release of grant under ResearchPromotion Scheme (RPS) during the financial year 2012-13to GNIPST as per the details below: a. Beneficiary Institution: Guru Nanak Institution of PharmaceuticalScience & Technology.

Click here to go at the top

15

04-11-2016

b. Principal Investigator: Dr. LopamudraDutta.

c. Grant-in-aid sanctioned:Rs. 16,25000/- onlyd. Approved duration: 3 years

e. Title of the project: Screening and identification of potentialmedicinal plant of Purulia & Bankura districts of West Bengal with respect to diseases such as diabetes, rheumatism, Jaundice, hypertension and developing biotechnological tools for enhancing bioactive molecules in these plants.

Activity Clubs of GNIPST: Name of Club Member Faculty CULTURAL Ms. Priyanka Ray DEBATE AND EXTEMPORE Mr. Soumya Bhattacharya ECO Ms. Sumana Roy LITERARY AND PAINTING Ms. Jeenatara Begum PHOTOGRAPHY Ms. Sanchari Bhattacharya and

Mr. Abir Koley SCIENCE AND INNOVATIVE MODELLING

Mr. Samrat Bose

SOCIAL SERVICES Dr. Asis Bala SPORTS Mr. Debabrata GhoshDastidar

Click here to go at the top

16